Irinotecan + capecitabine + oxaliplatin

Irinotecan + capecitabine + oxaliplatin is a combination chemotherapy regimen commonly referred to as XELOXIRI or Xeloxiri. It is primarily used in the treatment of metastatic colorectal cancer and consists of three cytotoxic agents: - **Irinotecan** is a prodrug converted to SN-38, which inhibits DNA topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing tumor cells. - **Capecitabine** is an oral prodrug that is metabolized to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts DNA synthesis. - **Oxaliplatin** is a platinum-based compound that forms both intra- and inter-strand crosslinks in DNA, preventing replication and transcription. This triplet regimen has demonstrated efficacy as first-line therapy for metastatic colorectal cancer patients, especially those who have progressed on standard doublet chemotherapies. The combination leverages different mechanisms of action for synergistic antitumor effects[1][2][3][4].

Brand names

XELOXIRI-3XELOXIRI3XELOXIRI 3

Other names

mIXO regimen